Alnylam Pharmaceuticals, founded in 2002, develops RNAi therapeutics that silence disease-causing genes, with a pipeline spanning rare and common diseases and 1,900+ employees globally.
Alnylam Pharmaceuticals, founded in 2002 and headquartered in Cambridge, Massachusetts, is the world's leading RNA interference (RNAi) therapeutics company. Its medicines work by silencing the genes that cause disease, addressing the underlying causes of illness rather than their symptoms. The company employs more than 1,900 people globally and has operated for over two decades.
The company's technical work spans RNAi therapeutics, gene silencing, genetic medicine, drug discovery and development, and biopharmaceutical manufacturing. Its pipeline comprises RNAi-based medicines for rare and common diseases, including TTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria. Alnylam runs an integrated model covering discovery, development, manufacturing and commercialisation, with commercial operations spanning multiple continents.
Alnylam operates across the biotechnology, biopharmaceuticals, rare diseases, genetic medicine and pharmaceuticals sectors. The company describes itself as mission-driven and committed to scientific excellence and innovation, and reports an award-winning culture that attracts top talent.
